31,681 Shares in Genmab A/S Sponsored ADR $GMAB Purchased by Callan Family Office LLC

Key Points

• Callan Family Office LLC purchased 31,681 shares of Genmab A/S for approximately $655,000 in the second quarter, indicating increased institutional interest in the company.
• Guggenheim and Zacks Research have upgraded Genmab A/S to a "buy" and "strong-buy" rating respectively, reflecting a positive outlook among analysts.
• Genmab A/S reported a quarterly earnings per share (EPS) of $0.54, surpassing analysts' expectations of $0.39, and generated $925 million in revenue for the quarter.

Callan Family Office LLC bought a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 31,681 shares of the company's stock, valued at approximately $655,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Foresight Group Ltd Liability Partnership acquired a new stake in shares of Genmab A/S during the first quarter worth about $954,000. Vident Advisory LLC acquired a new stake in shares of Genmab A/S during the first quarter worth about $242,000. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 1,465.3% during the first quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock worth $656,000 after purchasing an additional 31,343 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Genmab A/S during the second quarter worth about $257,000. Finally, Fifth Third Bancorp lifted its holdings in shares of Genmab A/S by 16.6% during the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock worth $825,000 after purchasing an additional 6,015 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on GMAB shares. Guggenheim raised Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 target price for the company in a report on Tuesday, September 23rd. Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 26th. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, HC Wainwright lifted their price target on Genmab A/S from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $40.80.

Genmab A/S Price Performance

Genmab A/S stock opened at $32.68 on Tuesday. The stock has a market capitalization of $20.98 billion, a PE ratio of 16.42, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $33.63. The business has a 50 day simple moving average of $27.07 and a 200-day simple moving average of $23.00.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The business had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.